Hypersomnolence, or excessive daytime sleepiness, can occur even after a person has 7 hours or more of quality sleep. Hypersomnolence categories include acute, subacute, and persistent. Other terms ...

Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to ...

Please provide your email address to receive an email when new articles are posted on . Older adults who reported hypersomnolence were more likely to have several other medical conditions, according ...

Findings from a retrospective study suggested a possible causal relationship between prior infection and the development of hypersomnolence disorders such as narcolepsy and idiopathic hypersomnia, but ...

Kleine-Levin syndrome is rare and difficult to diagnose, especially when symptoms are atypical. Recent research points to LMOD3 variations as a potential diagnostic marker if confirmed by further ...

WEST PALM BEACH, Fla., May 14, 2024 /PRNewswire/ -- Sleep Consortium, in partnership with leading sleep-related patient advocacy organizations, the global patient community, and key industry ...

Excessive daytime sleepiness (EDS) is not the same as feeling tired all the time. Instead, it’s a persistent urge to sleep during typical waking hours. EDS can be linked to a number of underlying ...

Hypersomnia, also known as hypersomnolence, refers to a condition of excessive sleepiness, which inhibits the ability of an individual to participate in everyday activities as normal. The symptoms ...

People with depression and a type of excessive sleepiness called hypersomnolence sleep for longer periods than healthy individuals, but sleep just as well, according to a February 1 study in the ...

Hypersomnia, also known as hypersomnolence, is a condition involving excessive daytime sleepiness or prolonged nighttime sleep on a recurring basis. Adolescents and young adults are most likely to be ...

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence BP1.15205 is a ...

PLYMOUTH MEETING, Pa., November 19, 2025--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, ...